Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $4 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a $4 price target.

August 16, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Lucid Diagnostics and maintained a $4 price target.
The news is directly about Lucid Diagnostics and its rating by Cantor Fitzgerald. The reiteration of an Overweight rating indicates that the analyst believes the company's stock will outperform the market, which could potentially attract investors. However, as this is a reiteration and not a change, the immediate impact on the stock price may be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100